Use of trimanganese tetraoxide particles in preparation of vaccine adjuvant
Disclosed is a use of trimanganese tetraoxide particles in preparation of a vaccine adjuvant. The adjuvant is a particle adjuvant, the particle adjuvant is trimanganese tetraoxide particles externally wrapped with or without an excipient, and the particle size of the particle adjuvant is 5 nm to 3000 nm. The trimanganese tetraoxide particle adjuvant provided in the present invention can be effectively combined with a single-stranded nucleotide adjuvant and can effectively carry an immune antigen, and a more excellent immunotherapy effects can be achieved when a fewer antigen dose and a relatively low injection amount are used; immune cells are efficiently activated, and body fluid balance and cellular immunity are achieved.
1 . An adjuvant composition comprising an adjuvant particle comprising:
(a) a trimanganese tetraoxide particle,
(b) a single nucleotide or a single-stranded nucleotide, and
(c) an excipient, wherein the excipient comprises a protein, a polypeptide, a polymer, a nucleic acid, or a polysaccharide, wherein the excipient and the single nucleotide or the single-stranded nucleotide form a covalent bond, and wherein the size of the adjuvant particle is about 5 nm to about 3000 nm, wherein the covalent bond is based on a chemically selective covalent modification group pair carried by the excipient and the single nucleotide or the single-stranded nucleotide.
2 . The adjuvant composition of claim 1 , wherein the single nucleotide or the single-stranded nucleotide comprises an oligonucleotide.
3 . The adjuvant composition of claim 2 , wherein the oligonucleotide comprises CpG oligodeoxynucleotides (CpG ODN).
4 . The adjuvant composition of claim 1 , wherein the single nucleotide or single-stranded nucleotide comprises a DNA fragment, an ATP, an ADP, or an AMP.
5 . The adjuvant composition of claim 1 , wherein the single nucleotide or single-stranded nucleotide comprises a modified DNA fragment, wherein the modified DNA fragment is a DNA fragment that has been subjected to functionalization of an amino functional group, a carboxyl functional group, a thiol functional group, or a chemically selective covalent modification group.
6 . The adjuvant composition of claim 1 , wherein the chemically selective covalent modification comprises maleimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, or succinimide.
7 . The adjuvant composition of claim 1 , wherein the molar ratio of manganese element in the trimanganese tetraoxide particles to the excipient is between 20:1 and 4000:1.
8 . An adjuvant composition comprising an adjuvant particle comprising:
(a) a trimanganese tetraoxide particle,
(b) a single nucleotide or a single-stranded nucleotide, wherein the single nucleotide or single-stranded nucleotide comprises a DNA fragment, an ATP, an ADP, or an AMP, and (c) an excipient, wherein the excipient comprises a protein, a polypeptide, a polymer, a nucleic acid, or a polysaccharide, wherein the excipient and the single nucleotide or the single-stranded nucleotide form a covalent bond, and wherein the size of the adjuvant particle is about 5 nm to about 3000 nm.
9 . The adjuvant composition of claim 8 , wherein the DNA fragment-single nucleotide or single-stranded nucleotide comprises a modified DNA fragment.
10 . The adjuvant composition of claim 9 , wherein the modified DNA fragment is a DNA fragment that has been subjected to functionalization of an amino functional group, a carboxyl functional group, a thiol functional group, or a chemically selective covalent modification group.
11 . The adjuvant composition of claim 9 , where the modified DNA fragment comprises a maleimidation, a succinimidation, or a 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.
12 . A vaccine comprising the adjuvant composition of claim 1 , wherein the adjuvant composition further comprises a vaccine antigen.
13 . The vaccine of claim 12 , wherein the vaccine antigen comprises one or more of a subunit antigen derived from an inactivated pathogen, a subunit antigen derived from an extracted pathogen subunit antigen, a recombinant subunit antigen, an antigenic epitope peptide, and a nucleic acid antigen.
14 . The vaccine of claim 13 , wherein the vaccine antigen comprises a subunit antigen derived from an inactivated pathogen or an extracted pathogen, wherein the pathogen is comprises includes a virus, a bacterium or a parasite.
15 . The vaccine of claim 14 , wherein the pathogen is comprises a virus.
16 . The vaccine of claim 15 , wherein the virus is a DNA virus or an RNA virus.
17 . The vaccine of claim 15 , wherein the virus is selected from the group consisting of: Coronavirus, Herpesviridae, Rhabdoviridae, Filoviridae, Orthomyxoviridae, Paramyxoviridae, Picornaviridae, Hepadnaviridae, Flaviviridae, Papillomaviridae, Poxviridae, and Retroviridae.
18 . The vaccine of claim 15 , wherein the virus is selected from the group consisting of coronavirus, influenza virus, herpes simplex virus, vesicular stomatitis virus, vaccinia virus, HIV and HBV.
19 . The vaccine of claim 15 , wherein the virus is a coronavirus or an influenza virus.
20 . The vaccine of claim 14 , wherein the pathogen is a parasite.
21 . The vaccine of claim 20 , wherein the parasite is selected from the group consisting of Plasmodium, Toxoplasma, Trypanosoma, Schistosoma, Filaria and Leishmania.